

Publications

Selected Publications

“Distinct roles for JNK1 and JNK2 in regulating JNK activity and c-Jun-dependent cell proliferation”. Sabapathy K*, Hochedlinger K, Nam SY, Bauer A, Karin M, Wagner EF. *Molecular Cell*. 2004. 15(5):713-25.

“p73 supports cellular growth through c-Jun-dependent AP-1 transactivation”. Vikhansyaka F, Toh WH, Dulloo I, Wu Q, Boominathan L, Ng HH, Vousden K, Sabapathy K. *Nature Cell Biol*. 2007. 9:698-705.

“The anti-apoptotic DeltaNp73 is degraded in a c-Jun-dependent manner upon genotoxic stress through the antizyme-mediated pathway”. Dulloo I, Gopalan G, Melino G, Sabapathy K. *Proc Nat Acad Sci*. 2010. 107:4902-7.

“Cell-type, dose and mutation-type specificity dictate mutant p53 functions in vivo.” Lee MK, Teoh WW, Phang BH, Tong WM, Wang ZQ and Sabapathy K. *Cancer Cell*. 2012. 22(6):751-64.

“Hypoxia-inducible TAp73 regulates the angiogenic transcriptome and supports tumorigenesis.” Dulloo I, Phang BH, Othman R, Tan SY, Vijayaraghavan A, Goh LK, Martin-Lopez M, Marques MM, Li CW, Wang DY, Marin MC, Xian W, McKeon F and Sabapathy K. *Nature Cell Biol*. 2015. 17(4):511-23.

“Molecular characterization of hepatocarcinogenesis using mouse models.” Teoh WW, Xie M, Vijayaraghavan A, Yaligar J, Tong WM, Goh LK and Sabapathy K. *Disease Models and Mechanisms*. 2015. 8(7):743-53.

“Amino-terminal p53 mutations lead to expression of apoptosis proficient p47 and prognosticate better survival, but predispose to tumorigenesis”. Phang BH, Othman R, Bougeard G, Chia RH, Frebourg T, Tang CL, Cheah PY, Sabapathy K. *Proc Natl Acad Sci U S A*. 2015. 112(46):6349-6358.

“Genome-wide AFB1-induced mutational signatures in cells, mice and human tumors – implications for molecular epidemiology”. Huang MN, Yi W, Teoh WW, Ardin M, Jusakul A, Ng A, Abedi-Ardekani B, Villar S, Myint SS, Othman R, Poon SL, Heguy A, Olivier M, Hollstein M, Tan P, Teh BT, Sabapathy K*, Zavadil J*, Rozen SG*. *Genome Biology*. 2017. 27(9):1475-1486.

“Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others”. Sabapathy K, Lane DP. *Nature Review Clinical Oncology*. 2018. 15(1):13-30.

“Novel tools for precision medicine - monoclonal antibodies against specific p53 hot-spot mutants”. Hwang LA, Phang BH, Liew OW, Iqbal J, Koh XH, Koh XY, Othman R, Xue Y, Richards AM, Lane DP*, Sabapathy K*. *Cell Reports*. 2018. 22:299-312.

“Cancer therapeutic targeting using mutant-p53-specific siRNAs”. Ubbly I, Krueger C, Rosato R, Qian W, Chang J, Sabapathy K. *Oncogene*. 2019. 38:3415-3427.

“Functional interaction between macrophages and hepatocytes dictate the outcome of liver fibrosis.” Xie M, Chia RH, Li D, Teo FX, Krueger C, Sabapathy K. *Life Sci Alliance*. 2021 4(4):e202000803.

“Cancer Cells Shuttle Extracellular Vesicles Containing Oncogenic Mutant p53 Proteins to the Tumor Microenvironment.” Bhatta B, Luz I, Krueger C, Teo FX, Lane DP, Sabapathy K, Cooks T. *Cancers (Basel)*. 2021 13(12):2985.